Tags : business

Lonza to Divest Specialty Ingredients Business to Bain Capital and

Tuba Khan February 10, 2021

Shots: Bain Capital and Cinven to acquire Lonza’s specialty ingredients business and operations for an enterprise value of $4.7B. The transaction is expected to close in H2’21 The divestiture will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Lonza’s specialty ingredients business provides microbial control solutions for Professional Hygiene […]Read More

M&A

Servier to Acquire Agios’ Oncology Business for ~$2B

Tuba Khan December 22, 2020

Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through the loss of exclusivity and 15% royalties on sales of vorasidenib in the US from first commercial sale through the loss of exclusivity The acquisition […]Read More

M&A

Boston Scientific to Divest BTG’s Specialty Pharma Business for ~$800M

Tuba Khan December 2, 2020

Shots: Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in H1’21 The agreement includes the transfer of 5 facilities & ~280 employees globally. This transaction will help the BTG specialty pharma business enhance its potential […]Read More

M&A

STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC

Tuba Khan February 25, 2020

Shots: STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020 The acquisition […]Read More

M&A

Zentiva to Acquire Alvogen’s Generics and OTC Business in Central

Vartika Singh October 25, 2019

Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be closed in Q1’20 The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen […]Read More

Animal Health M&A

Elanco To Acquire Bayer’s Animal Health Business for $7.6B

Tuba Khan August 20, 2019

Shots: Elanco acquires Bayer’s animal health business in cash & stock transaction, making a total deal value $7.6B. Bayer to get $5.32B cash as up front and $2.28B/~68M as Elanco’s common share with the expected closure of transaction in mid-2020 The focus of the acquisition is to strengthen & accelerating Elanco’s IPP strategy through a […]Read More

M&A Pharma

Pfizer’s Upjohn Off-Patent Drug Business to Merge with Mylan to

Tuba Khan July 29, 2019

Shots: Pfizer’s is expected to spin-off Upjohn and combine with Mylan in all-stock Reverse Morris Trust transaction, with each Mylan share to be converted into one share of the new company. Pfizer will hold 57% share while Mylan will hold 43% share of the newly formed company The merger will allow the new company to […]Read More

M&A

Novartis Announces Spin-Off of Alcon Eye Care Business on April

Tuba Khan March 22, 2019

Shots: Novartis plans spin-off of its eye care business with an expected 100% spin-off on Apr 9, 2019 and has secured debt financing of $3.5B through banks Novartis stockholder to receive Alcon share for every 5 Novartis shares/ADRs prior to the closing of trade on Apr 8, 2019 and will be listed on SIX and […]Read More

Pharma

Perrigo to Separate its Prescription Pharmaceutical Business

Vartika Singh August 9, 2018

Shots: Perrigo’s separated business helps it to lead the main focus on consumer business, which includes generic medicines including topical creams, foams, mousses, gels, liquids and inhalable products It may include a tax-efficient separation to shareholders, a sale or merger with no assurance as to form and timing of transaction This separation of […]Read More

Takeda Enters into an Exclusive License Agreement with Mirum to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receives the US FDA’s Approval for the Treatment of Retinal Vascular Disorders

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Tags : business

Lonza to Divest Specialty Ingredients Business to Bain Capital and

Servier to Acquire Agios’ Oncology Business for ~$2B

Boston Scientific to Divest BTG’s Specialty Pharma Business for ~$800M

STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC

Zentiva to Acquire Alvogen’s Generics and OTC Business in Central

Elanco To Acquire Bayer’s Animal Health Business for $7.6B

Pfizer’s Upjohn Off-Patent Drug Business to Merge with Mylan to

Novartis Announces Spin-Off of Alcon Eye Care Business on April

Perrigo to Separate its Prescription Pharmaceutical Business

Latest Posts

ViewPoints Article: 5 Technologies That Redefines Human Medicine and Therapeutics

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Tags : business

Latest Posts

Categories

Related Topics